Background: Hypovitaminosis D is associated with progression of renal disease, development of renal secondary hyperparathyroidism (RHPT), chronic kidney disease-mineral bone disorder (CKD-MBD), and increased mortality in people with CKD. Despite what is known regarding vitamin D dysregulation in humans with CKD, little is known about vitamin D metabolism in dogs with CKD.
C hronic kidney disease (CKD) in dogs is a condition characterized by progressive loss of function, with a reported prevalence of up to 25% of dogs. [1] [2] [3] Major consequences of CKD include development of renal secondary hyperparathyroidism (RHPT) and CKD-mineral bone disorder (CKD-MBD). In 1 study, by the International Renal Interest Society (IRIS) CKD staging system, the overall prevalence of RHPT in dogs was 76%, increasing from 36% for stage 2 to 100% for stage 4 dogs. 4 The development of RHPT is influenced by complex interactions of ionized calcium, phosphorus, vitamin D metabolites, parathyroid hormone (PTH), and fibroblast growth factor-23 [4] [5] [6] but only 1 study correlated these with IRIS stage. In that study, calcitriol concentrations were inversely associated with IRIS stage and PTH concentrations. 4 To our knowledge, no study has correlated 25(OH)D to IRIS stage, and no information on 24,25-dihydroxyvitamin D [24, 25(OH) 2 D] concentrations is available in dogs with clinical kidney disease.
Fibroblast growth factor-23 is secreted by osteocytes in response to net phosphate balance (i.e, dietary load, serum concentration), 1,25(OH) 2 D, and PTH. 7, 8 It promotes renal phosphorus excretion (i.e, acts as a phosphatonin) by suppressing 1a-hydroxylase activity (therefore decreasing 1,25(OH) 2 D synthesis) and renal sodium-phosphorus co-transporters. 7, [9] [10] [11] By increasing 24-hydroxylase activity, calcitriol concentrations are further decreased. 11 Fibroblast growth factor-23 directly decreases PTH secretion in early stages of CKD, but in more advanced stages of CKD, FGF-23 leads to decreased 1,25(OH) 2 D concentration that indirectly promotes development of RHPT, because adequate amounts of 1,25(OH) 2 D are needed to inhibit PTH gene transcription. 10 An additional mechanism for increased PTH is the development of FGF-23 resistance in the parathyroid glands because expression of its co-receptor klotho is decreased during CKD progression. 12 Increased FGF-23 is associated with progression of CKD, development of RHPT, and higher mortality rates in people. [13] [14] [15] Both PTH and FGF-23 can impact calcium and phosphorus concentrations. Both hormones tend to decrease circulating phosphorus whereas they have divergent effects on calcium. Whereas PTH tends to mobilize calcium, in part due to generation of calcitriol, FGF-23 minimizes calcium mobilization due to decreased calcitriol production. Calcium and phosphorus concentrations have been shown to be variably affected in CKD dogs with total calcium 9 phosphorus product (CPP) associated with IRIS stage and mortality. 4, 16, 17 Hypovitaminosis D and increased serum PTH and FGF-23 concentrations are associated with CKD progression, development of RHPT, and increased mortality in people with CKD. [18] [19] [20] Despite the clear role of vitamin D dysregulation in humans with CKD, information on vitamin D metabolites in dogs with different stages of renal disease is lacking. The primary goal of our study was to measure vitamin D metabolites, PTH, and FGF-23 concentrations in dogs with CKD and to determine their association with IRIS stages of CKD. We hypothesize that: (1) dogs with CKD will have lower vitamin D metabolite and higher PTH and FGF-23 concentrations than healthy dogs; and (2) these aberrations will be proportional to IRIS stage. A secondary goal of our study was to assess the relationship of calcium and phosphorus concentrations to IRIS stage. Lastly, we wanted to determine whether there was an association between vitamin D metabolites, specifically 25(OH)D, and dietary vitamin D (i.e, cholecalciferol) intake.
Materials & Methods

Case Selection Criteria
Client-owned dogs diagnosed with CKD were prospectively recruited from the patient population referred to The Ohio State University Veterinary Medical Center (OSU-VMC) between January 2014 and July 2015. A diagnosis of CKD was made based on the presence of at least 2 episodes, over at least 3 months, of minimally concentrated urine (urine specific gravity [USG] < 1.030) with or without azotemia in the absence of other diseases likely to cause polyuria or polydipsia. Additional factors used to determine eligibility included the presence of renal proteinuria, ultrasonographic changes consistent with CKD (e.g, loss of corticomedullary distinction) or both. Dogs were not consistently enrolled at the time of diagnosis, nor were all dogs enrolled in fasted states because of the manner in which dogs were presented to the teaching hospital. 
Study Design
After determining eligibility, each CKD dog had a complete physical examination performed, including body weight, body condition score (BCS), and muscle condition score (MCS). A Doppler systolic blood pressure was measured. Blood was collected by jugular venipuncture, and urine was collected by cystocentesis for CBC, serum biochemistry profile, serum ionized calcium concentration, urinalysis, urine culture, and urine protein:creatinine (UPC) ratio. Additional serum was stored at À80°C for analysis of vitamin D metabolite and PTH concentrations, and EDTA plasma was stored at À80°C for FGF-23 analysis. Information regarding medications, diets, and dietary supplements was recorded, and nutrient profiles of the diets the dogs were eating were obtained from the manufacturers. b Interassay coefficient of variation is reported to be 10%, intra-assay coefficient of variation is reported to be 3%, and functional sensitivity is reported to be 0.3 pmol/L for this assay. Plasma FGF-23 concentrations were measured using a humanspecific ELISA, c previously validated for measurement in dogs.
Vitamin D Analysis
Data Analysis
Concentrations were log-transformed before analysis to improve their normality and reduce heteroscedasticity. Results are presented as medians and ranges. Pearson correlations were used to assess the relationship between continuous variables. Analysis of variance was used to compare outcomes by IRIS stage, utilizing a Tukey-Kramer adjustment for multiple comparisons. Multivariable linear regression also was used to explore the relationship between vitamin D metabolites and the other relevant biomarkers, taking care to not include predictors that were collinear. Diagnostic plots of the residuals were used to assess model assumptions. Statistical analysis was performed using a commercial statistical software package.
d P-values ≤.05 were considered statistically significant.
Results
Thirty-seven dogs with IRIS stage 1-4 CKD and 10 control dogs were enrolled. Median age for CKD dogs was 10.2 years (range, 3.1-15.7 years). Median age for control dogs was 4.3 years (range, 1.4-10.3 years).
Breeds represented among CKD dogs were mixed breed (n = 15), Labrador Retriever (n = 4), and Golden Retriever (n = 3). There were 2 Cocker Spaniels, 2 Shetland Sheepdogs, and 1 each of the following breeds: Australian Cattle Dog, Boxer, Doberman, Fox Terrier, Greyhound, German Shepherd, Jack Russell Terrier, Miniature Schnauzer, Pekingese, Pomeranian, Shih Tzu, Vizsla, Weimaraner, Welsh Terrier, and Whippet. Sixteen male (15 castrated) and 21 female (20 spayed) dogs were included. Control dogs included mixed breed (n = 4), American Pit Bull Terrier (n = 3), German Shepherd (n = 2), and Rottweiler (n = 1). Six dogs were castrated males, and 4 were spayed females.
Median body weight of CKD dogs was 20.0 kg (range, 3.6-58.7 kg). Using the 9-point scoring system, median BCS was 6 (range, 2-8). Three dogs were underconditioned (BCS < 4), 15 dogs had an ideal BCS (4-5), and 19 dogs were overconditioned (BCS > 5). Body condition score was negatively correlated with serum creatinine concentration (r = À0.45; P = .002). The MCS was assessed to be normal in 26 dogs. Muscle loss was noted to be mild in 8 dogs, moderate in 1 dog, and severe in 2 dogs. Muscle condition did not correlate with IRIS stage. Median body weight of control dogs was 26.2 kg (range, 13.5-47.0 kg). Median BCS was 6 (range, 4.5-8). All control dogs had normal MCS.
IRIS Stages and Substages
According to the IRIS CKD staging system (Table 1) , dogs were classified as stage 1 (n = 10), stage 2 (n = 9), stage 3 (n = 12), or stage 4 (n = 6). Median serum creatinine concentration was 2.0 mg/dL (range, 0.5-12.9 mg/ dL). Median urine specific gravity was 1.013 (range, 1.003-1.028). Median urine protein:creatinine ratio (UPC) was 0.6 (range, 0.1-9.6). Based on IRIS substages, dogs were classified as nonproteinuric (n = 11), borderline proteinuric (n = 7), or proteinuric (n = 19). Three dogs had bacterial growth of Escherichia coli in their urine. One dog had light growth (600 colony-forming units [cfu] per mL), 1 had 30,000 cfu/mL, and 1 had >100,000 cfu/mL. Their UPC values were 1.2, 2.4, and 0.7, respectively. After removing these dogs from UPC calculations, the median UPC was 0.5. Median systolic blood pressure was 148 mm Hg (range, 115-240 mm Hg). Each dog received a blood pressure substage: minimal risk (n = 18), low risk (n = 5), moderate risk (n = 7), or high risk (n = 6). One dog did not have its blood pressure measured. None of the control dogs was proteinuric. One dog had an increased systolic blood pressure of 180 mm Hg. No specific underlying etiology was determined to account for this dog's hypertension.
Calcium and Phosphorus
Median serum total calcium concentration was 10.8 mg/dL (range, 8.1-13.0 mg/dL). It was within reference range (9.3-11.6 mg/dL) for 31 CKD dogs, low in 1 dog, and high in 5 dogs. Median serum ionized calcium concentration was 5.31 mg/dL (range, 4.03-6.02 mg/dL). Serum ionized calcium concentrations Table 1 . Laboratory parameters of chronic kidney disease (CKD) and healthy control dogs. . Of those dogs, stage 2 (n = 1), stage 3 (n = 3), and stage 4 (n = 5) CKD were represented. Serum CPP was negatively correlated with all vitamin D metabolites (Table 2; P < .001). Serum CPP was positively correlated with creatinine, PTH, and FGF-23 (P < .001).
Vitamin D Metabolites
All vitamin D metabolites were lower in CKD compared to healthy control dogs (Table 1) , reaching statistical significance with IRIS stages 3 and 4 (all adjusted P-values <.05). Vitamin D metabolite concentrations were not significantly different between controls and dogs with stages 1 and 2 CKD (Figs 1-3) . Serum creatinine concentration was negatively correlated with all vitamin D metabolites. Pearson correlation coefficients between vitamin D metabolites and creatinine, FGF-23, PTH, calcium, and phosphorus are listed in Table 2 .
Serum 25(OH)D concentration was negatively correlated with phosphorus (r = À0.55; P < .001), PTH (r = À0.42; P = .003), FGF-23 (r = À0.39; P = .009), and CPP (r = À0.43; P = .002). A doubling of serum creatinine concentration was associated with a 14% decrease in 25(OH)D (P = .005) (Fig 4) . Positive correlations were found between 25(OH)D and total calcium (r = 0.33; P = .02) and ionized calcium (r = 0.33; P = .047). Serum 1,25(OH)2D concentration was negatively correlated with FGF-23 (r = À0.64; P < .001), phosphorus (r = À0.61; P < .001), and PTH (r = À0.50; P < .001). Serum 24,25(OH) 2 D concentration was negatively correlated FGF-23 (r = À0.55; P < .001), phosphorus (r = À0.55; P < .001), and PTH (r = À0.48; P < .001).
PTH and FGF-23
Median PTH concentration in CKD dogs was 2.5 pmol/L (range, 0.8-229 pmol/L). Serum PTH was significantly higher in IRIS stage 3 (P = .0065) and stage 4 (P < .001) CKD dogs compared to healthy control dogs. Eight dogs had PTH concentrations above the upper limit of the laboratory's reference range of 5.8 pmol/L. Of these 8 dogs, 3 were classified as stage 3 CKD and 5 were classified as stage 4 CKD. These dogs had a median serum phosphorus concentration of 8.4 mg/dL (range, 2.7-14.4 mg/dL), notably higher than observed in dogs with lower stages of CKD. Median PTH in control dogs was 1.1 pmol/L (range, 0.7-7.8 pmol/L). One control dog had a serum PTH concentration above the upper limit of the laboratory's reference range. There was no identifiable disease present to explain it. There was no additional serum available to recheck this result from the time of enrollment, but approximately 18 months later, the dog had a normal serum PTH concentration of 1.2 pmol/L. Using this repeated result, median PTH concentration for control dogs was 1.1 pmol/L (range, 0.7-1.8 pmol/L). We hypothesize that this dog's blood was collected early in the morning and was affected by diurnal variation in serum PTH concentration in dogs. 22 Median FGF-23 concentration in 34 CKD dogs was 467 pg/mL (range, 142-41,265 pg/mL).
f As compared to control dogs, FGF-23 concentrations were significantly higher in CKD dogs with IRIS stages 3 and 4 disease (P < .001), but not between controls and earlier stages. Compared to the upper range of 449 pg/mL in the control dogs, 19 of 34 CKD dogs had high FGF-23 concentrations with a median of 2,520 pg/mL (range, 454-41,265 pg/mL). All IRIS stages were represented: stage 1 (n = 1), stage 2 (n = 2), stage 3 (n = 10), and stage 4 (n = 6). Three CKD dogs, IRIS stage 1 (n = 1) and stage 3 (n = 2), did not have their FGF-23 concentrations measured.
Medications and Diet
Dogs with CKD were receiving a variety of medications, including enalapril (n = 9), antibiotics (n = 6), aluminum hydroxide (n = 5), famotidine (n = 5), tramadol (n = 5), gabapentin (n = 4), omeprazole (n = 4), amlodipine (n = 3), ondansetron (n = 3), SC fluids (n = 3), diphenhydramine (n = 3), heartworm preventative (n = 3), mirtazapine (n = 2), phenylpropanolamine (n = 2), diethylstilbestrol (DES; n = 2), nonsteroidal anti-inflammatory drug (NSAID; n = 2), flea/tick preventative (n = 2), sevelamer (n = 1), maropitant (n = 1), soloxine (n = 1), trazodone (n = 1), aspirin (n = 1), and cyclosporine (n = 1). Eight control dogs were receiving heartworm and flea/tick preventatives.
At the time of enrollment, 17 dogs were reported to be eating ≥1 veterinary therapeutic renal diets and 18 dogs were eating a variety of other commercial diets. Two dogs were eating home-prepared diets. Most dogs were eating a predominantly dry kibble diet (n = 24). Ten dogs ate a combination of dry and canned diets, and 1 dog ate canned food exclusively. Almost all dogs (n = 34) were reported to receive a variety of treats and foods intended for human consumption. The specific amount of ingested cholecalciferol could not be determined given the variability in daily intake and the lack of many owners' abilities to provide exact amounts fed.
To assess for a relationship between dietary cholecalciferol intake and serum 25(OH)D concentrations, dietary intake was defined by the IU/100 kcal of cholecalciferol from the dog's primary diet source. The amount of dietary cholecalciferol ingested was unavailable for 6 dogs, 4 that were eating commercial diets and 2 that were eating variable home-prepared diets. There was no relationship between cholecalciferol intake and serum 25(OH)D (r = 0.19, P = .25).
Most CKD dogs (n = 20) were not receiving any dietary supplements. Supplements that were administered included fish oil (n = 10), joint health supplements (n = 7), multivitamin (n = 2), cranberry supplement (n = 2), symbiotic (n = 2), probiotic (n = 1), S-Adenosylmethionine/silybin (n = 1), niacinamide (n = 1), calcium carbonate (n = 1), calcitriol (n = 1), and vitamin E (n = 1). Four control dogs were receiving glucosamine supplements.
Discussion
In our study, we found CKD in dogs to be associated with a decrease in several vitamin D metabolites. Our results are consistent with previous studies that found 25 In our study, there was no well-defined relationship between dietary cholecalciferol intake, as defined by the IU/100 kcal of cholecalciferol from the dog's primary diet source, and 25(OH)D concentrations. The CKD dogs were eating a wide variety of diets, treats, and foods intended for human consumption, and did not consistently eat the same amounts on a daily basis. It has been shown that 82 healthy dogs eating the same diet can have quite variable serum 25(OH)D concentrations (personal communication, Dr. Rondo Middleton). It would have been ideal to determine what, if any, effect appetite and specific caloric intake had on serum 25(OH)D concentration.
One CKD dog was receiving calcium carbonate and calcitriol supplements, but this dog was eating an unbalanced home-cooked diet that was deficient in many essential nutrients, and it is unlikely that the calcium and calcitriol supplements were contributing any relevant quantities to affect systemic status. One CKD dog was receiving a glucosamine-chondroitin supplement that contained 500 IU cholecalciferol per tablet. g Based on the dog's estimated daily caloric intake, this added <0.5 IU/100 kcal, so it was unlikely to have made a relevant impact on systemic 25(OH)D status. Both dogs receiving multivitamin supplements were eating veterinary therapeutic renal diets, and it is unknown why they were receiving additional vitamin and mineral supplementation.
Another factor that could account for low 25(OH)D is that cholecalciferol may not be absorbed well in dogs with CKD. One study proposed that there may be a breed-associated effect related to intestinal absorption of cholecalciferol. 25 None of the dogs had known intestinal disease. Yet another possibility is that cholecalciferol is not as readily transformed in the liver to 25 (OH)D in animals with CKD. Decreased transformation of cholecalciferol to 25(OH)D has been demonstrated in rats with induced kidney disease as a result of decreased hepatic cytochrome P450 isoforms that affect 25-hydroxylase activity. 27 Proteinuria may influence 25(OH)D concentrations in dogs. 6 Lastly, BCS was negatively correlated with IRIS stage (i.e, serum creatinine concentration). The finding of poor condition with later stage CKD is likely multifactorial, resulting from decreased caloric intake and increased catabolic inflammatory cytokines. In a retrospective study, dogs with poor BCS (i.e, ≤ 3/9) had shorter survival than dogs with a BCS ≥ 4/9. 40 There was no association between BCS and vitamin D metabolites. It remains to be determined whether vitamin D metabolites are associated with survival in CKD dogs.
Limitations of this study included a relatively small number of dogs represented in each IRIS stage, especially stage 4. Study enrollment was not consistently performed on fasted patients. Some dogs may have been classified incorrectly based on the IRIS staging system, but we consider this unlikely. Other diseases that can cause polyuria and polydipsia could have been incorrectly classified as having IRIS stage 1 CKD. Many dogs did have abdominal ultrasound examinations performed, but dogs were not required to have this test performed nor were they required to have hyperadrenocorticism excluded. Dogs with neoplasia were excluded because there may be aberrations in calcium, vitamin D, and PTH metabolism in various types of cancers. 38, 41, 42 Another limitation is that control dogs were not agematched, but there was no difference in serum 25(OH)D concentration by age in 1 study of 320 dogs. 25 Three dogs had documented E. coli lower urinary tract infections, with mixed patterns of growth, ranging from mild (<600 cfu/mL) to heavy (>100,000 cfu/mL) quantitative growth. Infection is reported to affect UPC concentrations, although it is interesting to note that the dog with the heaviest growth had the lowest UPC (0.7) among the 3 dogs. None of the dogs exhibited overt clinical signs of pyelonephritis, but this possibility cannot be excluded. Although it is possible that these dogs may have been misclassified by IRIS stage, we consider this to be unlikely.
In summary, our study shows that vitamin D metabolites are decreased in CKD dogs and related to CKD severity. An inverse relationship exists between vitamin D metabolites and serum PTH, FGF-23, and phosphorus concentrations, supporting the complex relationship these hormones play in the development of RHPT. Additional studies are needed to determine whether targeted regulation of vitamin D metabolite status in dogs with CKD is warranted and the best way to increase vitamin D concentrations and decrease PTH and FGF-23 concentrations while avoiding toxicity (e.g, hypercalcemia). Historically, emphasis has been placed on supplementation with calcitriol, 43 
